#	Pagina
attuale pagina	/open-h2020/projects/225114/index.html
-1	/open-h2020/projects/212207/index.html

Opendata, web and dolomites

STRICT SIGNED

SN: The first blood biomarker to accurately STratify mortality Risk In patients with Cardiac arrhyTmia

Total Cost €

EC-Contrib. €

Partnership

Views

STRICT project word cloud

Explore the words cloud of the STRICT project. It provides you a very rough idea of what is the project "STRICT" about.

ecg 51 company detect device shown ventricle sudden competitive diagnostic diagnosis saving assurance 3b coming 67 blood cardiologists health acquiring least physical overtreatment recruit regime house victims quality lives 35 advantage ask cvd lt mortality burden defibrillator difficult eligible cardiovascular sn echocardiogram 20k biomedical data patients activated sme vitro left maturation ivd status caused arrythmia lvef biomarker disease accurate cardioverter skills expertise market icds scd positioning levels correlation survival never linked killer alone death patented reducing unknowingly cardinor innovation worldwide patient decision global secretoneurin associate implantable exams surgery pinpoint ejection normal boost globally cardiac biomarkers arrhythmias trl8 icd ventricular 25 stratify risk

Project "STRICT" data sheet

The following table provides information about the project.

Coordinator	CARDINOR AS Organization address address: GAUSTADALLEEN 21 city: OSLO postcode: 349 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Norway [NO]
Total cost	119˙805 €
EC max contribution	119˙805 € (100%)
Programme	1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
Code Call	H2020-INNOSUP-2019-02
Funding Scheme	CSA
Starting year	2019
Duration (year-month-day)	from 2019-12-15 to 2020-12-14

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CARDINOR AS CARDINOR AS Organization address address: GAUSTADALLEEN 21 city: OSLO postcode: 349 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (OSLO)	coordinator	119˙805.00

Map

Project objective

Cardiovascular disease (CVD) is the no. 1 killer worldwide. 25% of all CVD mortality is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival. To assess the patient’s status, cardiologists currently ask: physical exams, some cardiac biomarkers data, an ECG (which may detect an arrythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.3B€ overtreatment cost / year in the EU alone. CardiNor is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a globally patented biomarker and the only one shown to be specifically linked to ventricular arrhythmias. With SN data, cardiologists will be able to stratify patients according to their risk as well as to pinpoint high-risk patients not identified by the current diagnostic regime, thus reducing health burden costs and saving lives. CardiNor needs the SME Innovation Associate Programme to boost R&D activities within test maturation and effectively take it to TRL8. Currently, we do not have in-house expertise in biomedical device development or quality assurance. Therefore, we are looking to recruit an Innovation Associate. Acquiring these skills is important for CardiNor to maintain competitive advantage over coming years, positioning our company to high growth in the global CVD biomarkers market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

INNCAT2021 (2020)

Enhancing INNovation managament capacity of CATalan small and medium enterprises 2020 – 2021

3D-SE (2019)

Innovative digital, multi-parametric and predictable calculation model for the production of fibre reinforced 3D printed parts for aviation applications according to ISO9100